• AEGEAN Trial: New Data on Neoadjuvant Chemotherapy/Immunotherapy + Adjuvant Immunotherapy Released

    According to the preliminary results of the phase III AEGEAN trial (NCT03800134) interim analysis presented at the AACR Annual Meeting in 2023, in patients with resectable non-small cell lung cancer (NSCLC), the perioperative durvalumab combined with platinum-based neoadjuvant chemotherapy showed statistically significant improvements in pathological complete response (pCR) and event-free survival (EFS) compared to placebo…

  • Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

    Thymoma is one of the most common primary tumors in the anterior mediastinum, representing a group of diseases originating from different thymic epithelial cells, characterized by unique clinical and pathological features, often accompanied by various paraneoplastic syndromes. During the “Multidisciplinary Oncology Committee” session held at the 2023 European Lung Cancer Congress (ELCC), several experts discussed…

  • Interview with Dr. Martin Reck at ELCC 2023

    The 2023 European Lung Cancer Congress (ELCC) recently concluded in Copenhagen. In an interview with Oncology Frontier, 2023 ELCC Scientific Co-Chairs Professor Martin Reck reviewed the most significant oral presentations of the conference and shared insights on the selection of first-line immunotherapy regimens.

  • Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

    On the first day of the 2023 European Lung Cancer Congress (ELCC), during the oral presentation session, Dr. P. Garrido Lopez from Ramón y Cajal University Hospital in Madrid, Spain, presented the long-term efficacy, safety, and predictive factors of amivantamab in the treatment of platinum-treated EGFR exon 20 insertion (EGFR ex20ins) mutant advanced non-small cell…

  • Interview with Dr. Luis Paz-Ares: PD-L1 High Expression in Advanced NSCLC, IO Monotherapy vs. IO + Chemotherapy

    At the recently concluded 2023 European Lung Cancer Congress (ELCC), Professor Luis Paz-Ares from Madrid University Hospital in Spain presented results from a Phase II trial called CARMEN-LC05 (NCT04524689). The results showed that the antibody-drug conjugate (ADC) targeting CEACAM5, Tusamitamab ravtansineA, in combination with or without pembrolizumab, and chemotherapy, produced responses in CEACAM5-positive non-squamous non-small…

  • Dr. Ryan Jacobs: Bispecific Antibodies Bring New Progress in Follicular Lymphoma Treatment, New CD79b ADC Drugs Show Significant Value in DLBCL Treatment!

    The annual European Hematology Association (EHA) conference was recently held in Frankfurt, Germany, in a hybrid online and offline format. As the largest international conference in the European hematology field, the EHA meeting covered a wide range of scientific topics, clinical and basic research, including benign and malignant hematology, discussing the latest developments in the…

  • Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

    From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) was held in Frankfurt, Germany, both online and offline. The conference was hosted by the European Hematology Association. As the largest international conference in the European hematology field, it attracts over 10,000 professionals from more than 100 countries each year to share and…

  • Dr. Amir Fathi Interprets the Latest Developments in Targeted Therapy for Acute Myeloid Leukemia (AML)

    The annual European Hematology Association (EHA) meeting was successfully held both online and offline from June 8th to 11th, 2023, local time, in Frankfurt, Germany. As the largest international conference in the European hematology field, it attracts over ten thousand professionals from more than 100 countries every year, sharing and discussing innovative ideas and the…